Teleflex Launches Arrow JACC With Chloragard Technology

September 19, 2013—Teleflex Incorporated (Limerick, PA) announced the launch of the Arrow JACC (jugular axillo-subclavian central catheter), which features the company's Chloragard technology. The device is a small-French size antimicrobial and antithrombogenic catheter that is designed for both acute and long-term use. The Arrow JACC's Chloragard technology fights thrombosis and infection for up to 30 days and is effective against the full spectrum of bacterial and fungal pathogens. The Arrow JACC received US Food and Drug Administration clearance in November 2012.

According to the company, the Arrow JACC is designed specifically for vascular access specialists. Teleflex noted that it has developed a comprehensive education and training program focusing on the insertion of central venous catheters. This program is being licensed to institutions and academic medical centers to help grow vascular access teams and establish a high standard of care.

In Teleflex's press release, Darla Tarvin, RN, VA-BC, a vascular access specialist at Mercy Health-Clermont Hospital in Batavia, Ohio, commented, “As an early user of the JACC since April, the power and versatility of the device has become more evident the more that I use it. We have fully integrated its use into our renal practice and are expanding its use in other areas.”